NYSE:EW - Edwards Lifesciences Stock Price, Price Target & More

Get Started

$135.95 -1.62 (-1.18 %)

(As of 05/25/2018 04:00 PM ET)

Previous Close$135.95

Today's Range$135.25 - $137.82

52-Week Range$100.20 - $143.22

Volume1.00 million shs

Average Volume1.19 million shs

Market Capitalization$29.00 billion

P/E Ratio35.78

Dividend YieldN/A

Beta0.64

About Edwards Lifesciences (NYSE:EW)

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings and the beating-heart mitral repair systems; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient's physiological status; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

Receive EW News and Ratings via Email

Sign-up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical appliances & supplies

Sub-IndustryHealth Care Equipment

SectorMedical

SymbolNYSE:EW

CUSIP28176E10

Webwww.edwards.com

Phone949-250-2500

Debt

Debt-to-Equity Ratio0.14

Current Ratio2.07

Quick Ratio1.63

Price-To-Earnings

Trailing P/E Ratio35.78

Forward P/E Ratio29.36

P/E Growth2.02

Sales & Book Value

Annual Sales$3.44 billion

Price / Sales8.34

Cash Flow$4.2103 per share

Price / Cash32.29

Book Value$15.40 per share

Price / Book8.83

Profitability

EPS (Most Recent Fiscal Year)$3.80

Net Income$583.60 million

Net Margins17.36%

Return on Equity28.60%

Return on Assets15.89%

Miscellaneous

Employees12,200

Outstanding Shares210,780,000

Edwards Lifesciences (NYSE:EW) Frequently Asked Questions

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Edwards Lifesciences's stock split on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly issued shares were issued to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

How will Edwards Lifesciences' stock buyback program work?

Edwards Lifesciences declared that its Board of Directors has initiated a share repurchase plan on Thursday, December 7th 2017, which allows the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company's management believes its stock is undervalued.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences (NYSE:EW) posted its quarterly earnings results on Tuesday, April, 24th. The medical research company reported $1.22 earnings per share for the quarter, beating analysts' consensus estimates of $1.11 by $0.11. The medical research company had revenue of $938 million for the quarter, compared to analysts' expectations of $936.69 million. Edwards Lifesciences had a return on equity of 28.60% and a net margin of 17.36%. Edwards Lifesciences's revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the company posted $0.94 EPS. View Edwards Lifesciences' Earnings History.

When is Edwards Lifesciences' next earnings date?

Edwards Lifesciences is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Edwards Lifesciences.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences issued an update on its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share guidance of $4.50-$4.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.53. The company issued revenue guidance of $3.5-$3.9 billion, compared to the consensus revenue estimate of $3.85 billion.Edwards Lifesciences also updated its Q2 guidance to $1.05-$1.15 EPS.

What price target have analysts set for EW?

17 equities research analysts have issued 1-year price targets for Edwards Lifesciences' stock. Their predictions range from $115.00 to $180.00. On average, they expect Edwards Lifesciences' stock price to reach $149.1429 in the next twelve months. View Analyst Ratings for Edwards Lifesciences.

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a increase in short interest during the month of May. As of May 15th, there was short interest totalling 5,610,181 shares, an increase of 62.3% from the April 30th total of 3,456,057 shares. Based on an average daily volume of 1,266,171 shares, the days-to-cover ratio is currently 4.4 days. Approximately 2.7% of the company's shares are short sold.

Who are some of Edwards Lifesciences' key competitors?

Some companies that are related to Edwards Lifesciences include Intuitive Surgical (ISRG), Align Technology (ALGN), Zimmer Biomet (ZBH), Coloplast (CLPBY), Smith & Nephew (SNN), William Demant (WILYY), STERIS (STE), Inogen (INGN), Mine Safety Appliances (MSA), Wright Medical Group (WMGI), Halyard Health (HYH), Consort Medical (CSRMY), Invacare (IVC), Sientra (SIEN) and RTI Surgical (RTIX).

Who are Edwards Lifesciences' key executives?

Edwards Lifesciences' management team includes the folowing people:

Mr. Michael A. Mussallem, Chairman & CEO (Age 65)
Mr. Scott B. Ullem, Corp. VP & CFO (Age 51)
Mr. Donald E. Bobo Jr., Corp. VP of Strategy & Corp. Devel. (Age 56)
Mr. Larry L. Wood, Corp. VP of Transcatheter Heart Valve (Age 52)
Ms. Catherine M. Szyman, Corp. VP of Critical Care (Age 51)

Has Edwards Lifesciences been receiving favorable news coverage?

News headlines about EW stock have trended somewhat positive on Saturday, according to Accern. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Edwards Lifesciences earned a daily sentiment score of 0.22 on Accern's scale. They also assigned news coverage about the medical research company an impact score of 48.29 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.43%), American Century Companies Inc. (1.32%), Northern Trust Corp (1.13%), Wells Fargo & Company MN (1.06%), Disciplined Growth Investors Inc. MN (0.98%) and Massachusetts Financial Services Co. MA (0.97%). Company insiders that own Edwards Lifesciences stock include Bernard J Zovighian, Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Dylan Sidoo, Huimin Wang, Jean-Luc M Lemercier, John T Cardis, Kieran Gallahue, Larry L Wood, Michael A Mussallem, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences.

Which major investors are selling Edwards Lifesciences stock?

EW stock was sold by a variety of institutional investors in the last quarter, including Old Mutual Global Investors UK Ltd., WCM Investment Management CA, Sei Investments Co., Blair William & Co. IL, DekaBank Deutsche Girozentrale, Envestnet Asset Management Inc., Schroder Investment Management Group and Swiss National Bank. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences.

Which major investors are buying Edwards Lifesciences stock?

EW stock was acquired by a variety of institutional investors in the last quarter, including American Century Companies Inc., BlackRock Inc., OppenheimerFunds Inc., Rockefeller Capital Management L.P., Royal Bank of Canada, Chicago Capital LLC, Prudential Financial Inc. and Country Trust Bank. Company insiders that have bought Edwards Lifesciences stock in the last two years include Catherine M Szyman, Dylan Sidoo and Kieran Gallahue. View Insider Buying and Selling for Edwards Lifesciences.

How do I buy shares of Edwards Lifesciences?

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $135.95.

How big of a company is Edwards Lifesciences?

Edwards Lifesciences has a market capitalization of $29.00 billion and generates $3.44 billion in revenue each year. The medical research company earns $583.60 million in net income (profit) each year or $3.80 on an earnings per share basis. Edwards Lifesciences employs 12,200 workers across the globe.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]

MarketBeat Community Rating for Edwards Lifesciences (EW)

Community Ranking:		2.9 out of 5 ( )
Outperform Votes:		869 (Vote Outperform)
Underperform Votes:		635 (Vote Underperform)
Total Votes:		1,504

MarketBeat's community ratings are surveys of what our community members think about Edwards Lifesciences and other stocks. Vote "Outperform" if you believe EW will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EW will underperform the S&P 500 over the long term. You may vote once every thirty days.

Edwards Lifesciences (NYSE:EW) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

17 Wall Street analysts have issued ratings and price targets for Edwards Lifesciences in the last 12 months. Their average twelve-month price target is $149.1429, suggesting that the stock has a possible upside of 9.70%. The high price target for EW is $180.00 and the low price target for EW is $115.00. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.82	2.89	2.94	2.81
Ratings Breakdown:	0 Sell Rating(s) 3 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 3 Hold Rating(s) 14 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 15 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 5 Hold Rating(s) 15 Buy Rating(s) 1 Strong Buy Rating(s)
Consensus Price Target:	$149.1429	$148.0667	$141.9375	$124.9474
Price Target Upside:	9.70% upside	14.17% upside	7.39% upside	20.92% upside

Edwards Lifesciences (NYSE:EW) Consensus Price Target History

Price Target History for Edwards Lifesciences (NYSE:EW)

Edwards Lifesciences (NYSE:EW) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/23/2018	Royal Bank of Canada	Boost Price Target	Outperform	$145.00	High
4/25/2018	Northland Securities	Downgrade	Outperform ➝ Market Perform		High
4/10/2018	SunTrust Banks	Reiterated Rating	Buy	$180.00	Medium
3/20/2018	Cowen	Reiterated Rating	Buy	$165.00	Low
2/2/2018	Guggenheim	Reiterated Rating	Buy	$162.00	Low
2/2/2018	JMP Securities	Boost Price Target	Market Outperform ➝ Market Outperform	$135.00 ➝ $140.00	High
2/2/2018	Stifel Nicolaus	Reiterated Rating	Buy	$155.00	High
2/2/2018	Barclays	Boost Price Target	Overweight ➝ Overweight	$135.00 ➝ $155.00	High
2/2/2018	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$130.00 ➝ $138.00	High
2/2/2018	Canaccord Genuity	Reiterated Rating	Buy ➝ Buy	$140.00 ➝ $174.00	High
1/3/2018	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$140.00	High
1/2/2018	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral		Medium
12/8/2017	BMO Capital Markets	Reiterated Rating	Buy	$137.00	Low
10/26/2017	Deutsche Bank	Lower Price Target	Hold	$122.00 ➝ $115.00	N/A
8/28/2017	William Blair	Reiterated Rating	Outperform ➝ Outperform		Low
7/27/2017	Bank of America	Boost Price Target	Positive ➝ Buy	$140.00 ➝ $150.00	High
7/27/2017	Jefferies Group	Boost Price Target	Buy	$115.00 ➝ $132.00	High
5/16/2017	Goldman Sachs Group	Initiated Coverage	Conviction-Buy	$138.00	Low
2/8/2017	Credit Suisse Group	Set Price Target	Buy	$120.00	N/A
2/2/2017	Leerink Swann	Downgrade	Outperform ➝ Market Perform		N/A
2/2/2017	BTIG Research	Downgrade	Buy ➝ Neutral		N/A
9/11/2016	Wells Fargo & Co	Reiterated Rating	Buy		N/A
8/22/2016	UBS	Reiterated Rating	Buy		N/A
7/27/2016	Citigroup	Boost Price Target	Sell	$86.00 ➝ $94.00	N/A
6/21/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$123.00	N/A

(Data available from 5/26/2016 forward)

Edwards Lifesciences (NYSE:EW) Earnings History and Estimates Chart

Earnings by Quarter for Edwards Lifesciences (NYSE:EW)

Edwards Lifesciences (NYSE:EW) Earnings Estimates

2018 EPS Consensus Estimate: $4.47
2019 EPS Consensus Estimate: $5.14

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	4	$0.98	$1.12	$1.08
Q2 2018	4	$1.11	$1.16	$1.14
Q3 2018	4	$1.04	$1.07	$1.06
Q4 2018	4	$1.17	$1.21	$1.20
Q1 2019	3	$1.23	$1.31	$1.28
Q2 2019	3	$1.25	$1.34	$1.30
Q3 2019	3	$1.21	$1.22	$1.22
Q4 2019	3	$1.31	$1.40	$1.35

Edwards Lifesciences (NYSE EW) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/24/2018		$1.14					N/A
4/24/2018	Q1 2018	$1.11	$1.22	$936.69 million	$938.00 million	View	N/A
2/1/2018	Q4 2017	$0.91	$0.94	$868.45 million	$888.50 million	View	Listen
10/24/2017	Q3 2017	$0.86	$0.84	$833.85 million	$821.50 million	View	N/A
7/26/2017	Q2 2017	$0.88	$1.08	$839.16 million	$842.00 million	View	N/A
4/25/2017	Q1 2017	$0.82	$0.94	$776.51 million	$883.50 million	View	N/A
2/1/2017	Q416	$0.72	$0.75	$760.85 million	$767.70 million	View	N/A
10/25/2016	Q316	$0.68	$0.68	$749.14 million	$739.40 million	View	N/A
7/26/2016	Q216	$0.70	$0.76	$724.26 million	$759.30 million	View	N/A
4/26/2016	Q116	$0.66	$0.71	$664.53 million	$697.30 million	View	N/A
2/2/2016	Q415	$0.62	$0.63	$647.44 million	$671.10 million	View	N/A
10/26/2015	Q315	$0.98	$1.07	$598.29 million	$615.00 million	View	N/A
7/28/2015	Q215	$1.05	$1.13	$604.97 million	$616.80 million	View	N/A
4/23/2015	Q115	$1.04	$1.12	$585.16 million	$590.30 million	View	N/A
2/3/2015	Q414	$0.95	$1.06	$610.50 million	$618.00 million	View	Listen
10/23/2014	Q314	$0.72	$0.80	$546.10 million	$607.40 million	View	Listen
7/29/2014	Q214	$0.77	$0.88	$545.10 million	$547.00 million	View	Listen
4/24/2014	Q114	$0.69	$0.76	$523.10 million	$522.40 million	View	Listen
2/3/2014	Q413	$0.82	$0.91	$533.82 million	$536.00 million	View	N/A
10/28/2013	Q313	$0.66	$0.68	$490.96 million	$496.00 million	View	N/A
7/25/2013	Q2 2013	$0.76	$0.82	$514.59 million	$517.20 million	View	N/A
4/23/2013	Q1 2013	$0.76	$0.72	$518.69 million	$496.70 million	View	N/A
2/4/2013	Q4 2012	$0.77	$0.77	$499.46 million	$510.50 million	View	N/A
10/19/2012		$0.56	$0.58			View	N/A
7/24/2012		$0.66	$0.67			View	N/A
4/24/2012	Q1 2012	$0.24	$0.27			View	N/A
2/2/2012		$0.59	$0.62			View	N/A
10/19/2011		$0.39	$0.38			View	N/A
7/21/2011		$0.50	$0.49			View	N/A
4/20/2011		$0.42	$0.51			View	N/A
2/2/2011		$0.53	$0.55			View	N/A
10/25/2010	Q3 2010	$0.21	$0.21			View	N/A
7/21/2010	Q2 2010	$0.22	$0.23			View	N/A
4/20/2010	Q1 2010	$0.20	$0.20			View	N/A
2/4/2010	Q4 2009	$0.21	$0.21			View	N/A
10/21/2009	Q3 2009	$0.18	$0.18			View	N/A
7/20/2009	Q2 2009	$0.19	$0.20			View	N/A
4/27/2009	Q1 2009	$0.17	$0.18			View	N/A
2/3/2009	Q4 2008	$0.19	$0.19			View	N/A
10/21/2008	Q3 2008	$0.14	$0.14			View	N/A
7/22/2008	Q2 2008	$0.16	$0.16			View	N/A
4/22/2008	Q1 2008	$0.12	$0.14			View	N/A
2/5/2008	Q4 2007	$0.13	$0.14			View	N/A

(Earnings results data provided by Zacks Investment Research)

Edwards Lifesciences (NYSE:EW) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Edwards Lifesciences (NYSE EW) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.84%
Institutional Ownership Percentage: 81.03%

Insider Trading History for Edwards Lifesciences (NYSE:EW)

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Edwards Lifesciences (NYSE EW) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/24/2018	Catherine M Szyman	VP	Sell	9,815	$139.39	$1,368,112.85	20,012
5/17/2018	Michael A Mussallem	CEO	Sell	32,900	$135.88	$4,470,452.00	112,731
5/15/2018	Larry L. Wood	VP	Sell	6,300	$137.26	$864,738.00
5/9/2018	Jean-Luc M Lemercier	VP	Sell	5,634	$134.91	$760,082.94	38,784
5/9/2018	Scott B Ullem	CFO	Sell	25,000	$134.73	$3,368,250.00	35,968
5/7/2018	Michael A Mussallem	CEO	Sell	32,800	$136.37	$4,472,936.00	61,131
5/4/2018	Huimin Wang	VP	Sell	3,800	$131.93	$501,334.00	85,016
4/30/2018	Michael A Mussallem	CEO	Sell	32,800	$128.46	$4,213,488.00	74,131
4/16/2018	Larry L. Wood	VP	Sell	6,300	$138.97	$875,511.00
4/11/2018	Jean-Luc M. Lemercier	VP	Sell	5,633	$139.42	$785,352.86
4/4/2018	Donald E. Bobo, Jr.	VP	Sell	4,000	$134.78	$539,120.00
4/4/2018	Scott B Ullem	CFO	Sell	25,000	$137.17	$3,429,250.00	35,968
3/29/2018	Donald E Bobo Jr	VP	Sell	5,300	$138.58	$734,474.00	24,908
3/28/2018	Scott B Ullem	CFO	Sell	25,000	$137.33	$3,433,250.00	35,968
3/21/2018	Michael A Mussallem	CEO	Sell	32,800	$139.74	$4,583,472.00	74,131
3/19/2018	Huimin Wang	VP	Sell	3,800	$141.84	$538,992.00
3/15/2018	Larry L Wood	VP	Sell	6,300	$141.49	$891,387.00	116,148
3/7/2018	Jean-Luc M Lemercier	VP	Sell	5,633	$136.29	$767,721.57	44,298
2/20/2018	Donald E Bobo Jr	VP	Sell	5,300	$134.70	$713,910.00	24,908
2/16/2018	Larry L Wood	VP	Sell	6,300	$134.27	$845,901.00	116,148
2/13/2018	Michael A Mussallem	CEO	Sell	32,800	$126.69	$4,155,432.00	74,131
2/12/2018	Donald E Bobo Jr	VP	Sell	3,750	$127.54	$478,275.00	19,608
2/9/2018	William J Phd Link	Director	Sell	12,000	$122.24	$1,466,880.00	24,596
2/5/2018	Robert W.A. Sellers	VP	Sell	12,020	$131.03	$1,574,980.60
1/29/2018	Donald E Bobo Jr	VP	Sell	5,300	$127.24	$674,372.00	24,908
1/16/2018	Larry L Wood	VP	Sell	6,300	$121.00	$762,300.00	116,148
1/4/2018	Michael A. Mussallem	CEO	Sell	32,800	$114.97	$3,771,016.00
12/28/2017	Donald E. Bobo, Jr.	VP	Sell	5,300	$114.08	$604,624.00
12/28/2017	Donald E. Bobo, Jr.	VP	Sell	5,300	$114.08	$604,624.00
12/19/2017	Michael A. Mussallem	CEO	Sell	32,800	$114.82	$3,766,096.00
12/15/2017	Larry L. Wood	VP	Sell	18,960	$114.58	$2,172,436.80
11/29/2017	Donald E. Bobo, Jr.	VP	Sell	5,300	$116.45	$617,185.00
11/20/2017	Michael A. Mussallem	CEO	Sell	32,900	$106.86	$3,515,694.00
11/15/2017	Larry L. Wood	VP	Sell	18,960	$104.76	$1,986,249.60
11/9/2017	Schack Wesley W Von	Director	Sell	1,000	$104.15	$104,150.00	2,622
10/30/2017	Donald E. Bobo, Jr.	VP	Sell	5,300	$101.12	$535,936.00
10/30/2017	Michael A. Mussallem	CEO	Sell	32,900	$100.93	$3,320,597.00
10/16/2017	Larry L Wood	VP	Sell	18,960	$108.54	$2,057,918.40
9/29/2017	Donald E. Bobo, Jr.	VP	Sell	5,300	$108.86	$576,958.00
9/15/2017	Larry L. Wood	VP	Sell	18,960	$112.58	$2,134,516.80
9/7/2017	Michael A. Mussallem	CEO	Sell	32,900	$112.45	$3,699,605.00
8/30/2017	Larry L. Wood	VP	Sell	18,960	$111.81	$2,119,917.60
8/29/2017	Donald E. Bobo, Jr.	VP	Sell	5,300	$112.15	$594,395.00
8/9/2017	Michael A. Mussallem	CEO	Sell	32,900	$115.99	$3,816,071.00
8/4/2017	Donald E. Bobo, Jr.	VP	Sell	25,000	$116.00	$2,900,000.00
7/31/2017	Catherine M. Szyman	VP	Sell	4,681	$115.78	$541,966.18
7/31/2017	Michael A. Mussallem	CEO	Sell	32,900	$114.80	$3,776,920.00
7/28/2017	Donald E. Bobo, Jr.	VP	Sell	5,300	$114.68	$607,804.00
6/29/2017	Donald E. Bobo, Jr.	VP	Sell	5,600	$117.15	$656,040.00
6/7/2017	Michael A. Mussallem	CEO	Sell	32,900	$118.05	$3,883,845.00
5/31/2017	Patrick B. Verguet	VP	Sell	10,000	$114.88	$1,148,800.00
5/19/2017	Dylan Sidoo	Director	Buy	25,000	$0.11	$2,750.00
5/19/2017	Patrick B. Verguet	VP	Sell	22,631	$113.16	$2,560,923.96
5/15/2017	Patrick B. Verguet	VP	Sell	11,500	$111.64	$1,283,860.00
5/8/2017	Donald E. Bobo, Jr.	VP	Sell	19,100	$110.34	$2,107,494.00
5/4/2017	Donald E. Bobo, Jr.	VP	Sell	34,120	$109.98	$3,752,517.60
5/3/2017	Michael A. Mussallem	CEO	Sell	49,100	$109.71	$5,386,761.00
4/28/2017	Michael A. Mussallem	CEO	Sell	49,100	$109.78	$5,390,198.00
4/27/2017	Bernard J. Zovighian	VP	Sell	18,050	$109.21	$1,971,240.50
4/5/2017	Donald E. Bobo, Jr.	VP	Sell	13,720	$93.58	$1,283,917.60
3/30/2017	Patrick B. Verguet	VP	Sell	24,000	$93.90	$2,253,600.00
3/6/2017	Donald E. Bobo, Jr.	VP	Sell	13,720	$90.01	$1,234,937.20
2/16/2017	Michael A. Mussallem	CEO	Sell	49,100	$89.63	$4,400,833.00
2/3/2017	Kieran Gallahue	Director	Buy	3,000	$90.10	$270,300.00	2,524
1/13/2017	Michael A. Mussallem	CEO	Sell	49,100	$97.08	$4,766,628.00
1/12/2017	Donald E. Bobo, Jr.	VP	Sell	13,720	$97.47	$1,337,288.40
1/12/2017	Dylan Sidoo	Director	Buy	30,000	$0.13	$3,900.00
1/11/2017	Dylan Sidoo	Director	Buy	20,000	$0.13	$2,600.00
12/19/2016	Michael A. Mussallem	CEO	Sell	49,100	$91.96	$4,515,236.00
12/5/2016	Huimin Wang	VP	Sell	13,650	$83.53	$1,140,184.50
12/1/2016	Larry L. Wood	VP	Sell	13,258	$81.85	$1,085,167.30
11/30/2016	Catherine M. Szyman	VP	Buy	12,870	$83.43	$1,073,744.10
11/29/2016	Kieran Gallahue	Director	Buy	3,000	$84.63	$253,890.00
11/22/2016	Michael A. Mussallem	CEO	Sell	49,100	$84.67	$4,157,297.00
11/7/2016	Huimin Wang	VP	Sell	13,650	$91.29	$1,246,108.50
11/2/2016	Donald E. Bobo, Jr.	VP	Sell	15,000	$90.13	$1,351,950.00
11/1/2016	Larry L. Wood	VP	Sell	13,257	$93.27	$1,236,480.39
10/27/2016	Michael A. Mussallem	CEO	Sell	49,100	$92.77	$4,555,007.00
10/5/2016	Huimin Wang	VP	Sell	13,650	$120.04	$1,638,546.00
10/3/2016	Larry L. Wood	VP	Sell	13,257	$119.27	$1,581,162.39
9/6/2016	Huimin Wang	VP	Sell	13,650	$115.72	$1,579,578.00
9/2/2016	Donald E. Bobo, Jr.	VP	Sell	18,000	$115.78	$2,084,040.00
8/26/2016	Patrick B. Verguet	VP	Sell	5,000	$114.88	$574,400.00
8/24/2016	Patrick B. Verguet	VP	Sell	5,000	$116.81	$584,050.00
8/23/2016	Patrick B. Verguet	VP	Sell	10,092	$117.53	$1,186,112.76
8/11/2016	Michael A. Mussallem	CEO	Sell	49,100	$114.01	$5,597,891.00
8/10/2016	John T. Cardis	Director	Sell	5,000	$113.21	$566,050.00
8/9/2016	Patrick B. Verguet	VP	Sell	10,000	$113.48	$1,134,800.00
8/5/2016	Huimin Wang	VP	Sell	13,650	$113.03	$1,542,859.50
8/1/2016	Larry L. Wood	VP	Sell	13,257	$114.24	$1,514,479.68
8/1/2016	Schack Wesley W. Von	Director	Sell	6,000	$113.98	$683,880.00
7/29/2016	Robert W.A. Sellers	VP	Sell	10,000	$114.33	$1,143,300.00
7/28/2016	Michael A. Mussallem	CEO	Sell	49,100	$113.31	$5,563,521.00
7/5/2016	Huimin Wang	VP	Sell	13,650	$98.44	$1,343,706.00
7/1/2016	Larry L. Wood	VP	Sell	13,257	$98.79	$1,309,659.03
6/8/2016	Michael A Mussallem	CEO	Sell	49,100	$102.75	$5,045,025.00	127,341
6/6/2016	Huimin Wang	VP	Sell	13,650	$101.34	$1,383,291.00	89,272
6/3/2016	Larry L Wood	VP	Sell	13,257	$101.38	$1,343,994.66	115,083
5/31/2016	Donald E Bobo Jr	VP	Sell	18,000	$99.04	$1,782,720.00	62,796
5/24/2016	Steven R Loranger	Director	Buy	5,000	$101.07	$505,350.00	1,941
5/18/2016	Patrick B Verguet	VP	Sell	13,000	$102.75	$1,335,750.00	129,944
5/17/2016	Patrick B Verguet	VP	Sell	5,000	$105.00	$525,000.00	129,944
5/16/2016	Patrick B Verguet	VP	Sell	3,000	$104.62	$313,860.00	129,944
5/5/2016	Huimin Wang	VP	Sell	13,650	$103.36	$1,410,864.00	81,480
5/5/2016	Michael A Mussallem	CEO	Sell	59,000	$104.12	$6,143,080.00	68,256
5/2/2016	Patrick B Verguet	VP	Sell	7,000	$106.86	$748,020.00	115,107
4/29/2016	Michael A Mussallem	CEO	Sell	59,000	$106.13	$6,261,670.00	79,256
4/5/2016	Huimin Wang	VP	Sell	13,650	$103.97	$1,419,190.50	81,480
3/17/2016	Michael A Mussallem	CEO	Sell	59,000	$84.39	$4,979,010.00	80,650
3/7/2016	Huimin Wang	VP	Sell	13,650	$87.17	$1,189,870.50	81,299
2/18/2016	Michael A. Mussallem	CEO	Sell	59,000	$86.94	$5,129,460.00
2/18/2016	Patrick B. Verguet	VP	Sell	5,000	$87.00	$435,000.00
2/16/2016	Patrick B. Verguet	VP	Sell	8,000	$81.58	$652,640.00
2/5/2016	Huimin Wang	VP	Sell	13,650	$83.46	$1,139,229.00
2/4/2016	Barbara J. Mcneil	Director	Sell	4,000	$83.29	$333,160.00
1/21/2016	Patrick B. Verguet	VP	Sell	8,000	$77.00	$616,000.00	99,803
1/6/2016	Nick Demare	Director	Buy	15,000	$0.08	$1,200.00
1/5/2016	Huimin Wang	VP	Sell	13,650	$78.50	$1,071,525.00	67,649
1/5/2016	Michael A. Mussallem	CEO	Sell	59,000	$79.82	$4,709,380.00	21,650
12/17/2015	Michael A. Mussallem	CEO	Sell	59,000	$81.85	$4,829,150.00	21,650
12/15/2015	Patrick B. Verguet	VP	Sell	8,000	$80.87	$646,960.00	99,803
12/4/2015	Huimin Wang	VP	Sell	6,880	$157.96	$1,086,764.80	33,824
11/27/2015	Patrick B. Verguet	VP	Sell	7,500	$164.50	$1,233,750.00	49,901
11/23/2015	Robert W.A. Sellers	VP	Sell	19,200	$157.13	$3,016,896.00	13,158
11/17/2015	Patrick B. Verguet	VP	Sell	4,000	$154.50	$618,000.00	49,901
11/5/2015	Huimin Wang	VP	Sell	6,920	$156.01	$1,079,589.20	34,174
11/3/2015	Patrick B. Verguet	VP	Sell	4,338	$158.48	$687,486.24	49,901
10/30/2015	Patrick B. Verguet	VP	Sell	22,000	$155.09	$3,411,980.00	49,901
10/29/2015	Michael A Mussallem	CEO	Sell	29,500	$154.59	$4,560,405.00	40,325
10/5/2015	Huimin Wang	VP	Sell	6,920	$154.30	$1,067,756.00	34,174
10/2/2015	Patrick B. Verguet	VP	Sell	4,000	$154.00	$616,000.00	53,901
10/1/2015	Larry L. Wood	VP	Sell	7,680	$141.52	$1,086,873.60	43,838
9/21/2015	Michael A. Mussallem	CEO	Sell	29,500	$142.49	$4,203,455.00	10,825
9/4/2015	Huimin Wang	VP	Sell	6,920	$135.19	$935,514.80	34,174
9/1/2015	Larry L. Wood	VP	Sell	7,680	$137.50	$1,056,000.00	43,838
8/24/2015	Michael A. Mussallem	CEO	Sell	29,500	$135.25	$3,989,875.00	279,887
8/13/2015	West Petroleum Corp. East	Insider	Buy	25,000	$0.1150	$2,875.00
7/6/2015	Huimin Wang	VP	Sell	6,920	$143.95	$996,134.00
7/1/2015	Larry L Wood	VP	Sell	7,680	$143.51	$1,102,156.80
6/24/2015	Michael A Mussallem	CEO	Sell	29,500	$143.71	$4,239,445.00
6/5/2015	Huimin Wang	VP	Sell	6,920	$131.39	$909,218.80
6/1/2015	Larry L Wood	VP	Sell	7,680	$130.47	$1,002,009.60
5/29/2015	Patrick B Verguet	VP	Sell	9,662	$131.18	$1,267,461.16
5/21/2015	Barbara J Mcneil	Director	Sell	2,000	$132.59	$265,180.00
5/19/2015	Robert Marc Bustin	Director	Sell	10,000	$0.1750	$1,750.00
5/1/2015	Larry L Wood	VP	Sell	7,680	$127.12	$976,281.60
4/30/2015	Michael A Mussallem	CEO	Sell	29,500	$128.99	$3,805,205.00
4/6/2015	Huimin Wang	VP	Sell	6,920	$140.24	$970,460.80
4/1/2015	Larry L Wood	VP	Sell	7,680	$142.06	$1,091,020.80
3/31/2015	Robert Marc Bustin	Director	Buy	15,000	$0.15	$2,250.00
3/26/2015	Michael A Mussallem	CEO	Sell	29,500	$140.10	$4,132,950.00
3/2/2015	Larry L Wood	VP	Sell	7,680	$132.62	$1,018,521.60
2/6/2015	Huimin Wang	VP	Sell	6,920	$134.79	$932,746.80
1/5/2015	Huimin Wang	VP	Sell	6,920	$126.60	$876,072.00
1/5/2015	Michael A Mussallem	CEO	Sell	29,500	$128.20	$3,781,900.00
12/22/2014	Michael A Mussallem	CEO	Sell	29,500	$133.01	$3,923,795.00
11/24/2014	Michael A Mussallem	CEO	Sell	29,500	$124.25	$3,665,375.00
11/13/2014	Robert W.A. Sellers	VP	Sell	3,400	$124.27	$422,518.00
11/10/2014	Patrick B Verguet	VP	Sell	5,000	$123.70	$618,500.00
11/7/2014	Schack Wesley W Von	Director	Sell	3,655	$123.00	$449,565.00
11/5/2014	Huimin Wang	VP	Sell	5,600	$120.26	$673,456.00
10/28/2014	Barbara J Mcneil	Director	Sell	1,000	$117.94	$117,940.00
10/28/2014	Michael A Mussallem	CEO	Sell	29,500	$117.06	$3,453,270.00
10/28/2014	Patrick B Verguet	VP	Sell	15,000	$117.33	$1,759,950.00
10/28/2014	West Petroleum Corp. East	Insider	Buy	15,000	$0.12	$1,800.00
10/27/2014	Patrick B Verguet	VP	Sell	10,000	$117.00	$1,170,000.00
10/27/2014	West Petroleum Corp. East	Insider	Buy	20,000	$0.13	$2,600.00
10/24/2014	Donald E Bobo Jr	VP	Sell	30,000	$114.25	$3,427,500.00
10/24/2014	West Petroleum Corp. East	Insider	Buy	35,000	$0.1350	$4,725.00
10/23/2014	West Petroleum Corp. East	Insider	Buy	40,000	$0.1450	$5,800.00
10/6/2014	Huimin Wang	VP	Sell	5,600	$107.00	$599,200.00
10/3/2014	Donald E Bobo Jr	VP	Sell	25,000	$105.00	$2,625,000.00
9/29/2014	Michael A Mussallem	CEO	Sell	29,500	$102.71	$3,029,945.00
9/10/2014	Donald E Bobo Jr	VP	Sell	25,000	$100.00	$2,500,000.00
9/5/2014	Huimin Wang	VP	Sell	5,600	$98.29	$550,424.00
8/27/2014	Carlyn D Solomon	VP	Sell	85,200	$97.85	$8,336,820.00
8/27/2014	Michael A Mussallem	CEO	Sell	29,500	$98.14	$2,895,130.00
8/18/2014	John T Cardis	Director	Sell	6,000	$97.92	$587,520.00
8/18/2014	Larry L Wood	VP	Sell	63,752	$97.85	$6,238,133.20
8/13/2014	Patrick B Verguet	VP	Sell	7,800	$95.50	$744,900.00
8/5/2014	Patrick B Verguet	VP	Sell	15,000	$94.05	$1,410,750.00
8/4/2014	Patrick B Verguet	VP	Sell	5,000	$93.00	$465,000.00
8/1/2014	Patrick B Verguet	VP	Sell	5,000	$92.00	$460,000.00
7/31/2014	Michael A Mussallem	CEO	Sell	29,500	$91.98	$2,713,410.00
7/31/2014	Robert Alexander Ingram	Director	Sell	12,500	$90.26	$1,128,250.00
7/31/2014	Robert W.A. Sellers	VP	Sell	8,850	$91.47	$809,509.50
7/30/2014	Donald E Bobo Jr	VP	Sell	23,270	$92.00	$2,140,840.00
7/7/2014	Huimin Wang	VP	Sell	5,600	$87.79	$491,624.00
6/27/2014	Donald E Bobo Jr	VP	Sell	25,000	$87.00	$2,175,000.00
6/24/2014	Michael A Mussallem	CEO	Sell	29,500	$85.38	$2,518,710.00
6/5/2014	Huimin Wang	VP	Sell	5,600	$80.73	$452,088.00
5/30/2014	Barbara J Mcneil	Director	Sell	1,200	$81.20	$97,440.00
5/28/2014	Michael A Mussallem	CEO	Sell	29,500	$79.33	$2,340,235.00
4/14/2014	Donald Bobo, Jr.	VP	Sell	25,000	$82.00	$2,050,000.00	20,604
4/10/2014	Michael Mussallem	CEO	Sell	29,500	$74.71	$2,203,945.00	263,850
4/7/2014	Huimin Wang	VP	Sell	5,600	$74.03	$414,568.00	31,549
3/24/2014	Michael Bowlin	Director	Sell	1,093	$72.33	$79,056.69	77,199
3/6/2014	Robert W.A. Sellers	VP	Sell	1,650	$72.88	$120,252.00	20,570
2/6/2014	Michael Mussallem	CEO	Sell	29,500	$66.92	$1,974,140.00	263,850
1/27/2014	Michael Bowlin	Director	Sell	1,092	$68.65	$74,965.80	77,199
1/9/2014	Michael Mussallem	CEO	Sell	29,500	$67.04	$1,977,680.00	263,850
1/6/2014	Huimin Wang	VP	Sell	5,600	$67.14	$375,984.00	31,337
12/11/2013	Patrick Verguet	VP	Sell	10,000	$62.34	$623,400.00	48,681
12/5/2013	Huimin Wang	VP	Sell	4,650	$64.65	$300,622.50	31,337
12/4/2013	Michael Mussallem	CEO	Sell	29,500	$64.90	$1,914,550.00	263,850
10/9/2013	Michael Mussallem	CEO	Sell	29,500	$72.63	$2,142,585.00	263,850
10/4/2013	Huimin Wang	VP	Sell	4,850	$72.19	$350,121.50	31,337
9/12/2013	Michael Mussallem	CEO	Sell	29,500	$71.82	$2,118,690.00	263,850
9/5/2013	Huimin Wang	VP	Sell	4,850	$71.24	$345,514.00	31,337
8/8/2013	Michael Mussallem	CEO	Sell	29,500	$72.28	$2,132,260.00	263,850
8/5/2013	Huimin Wang	VP	Sell	4,850	$72.30	$350,655.00	31,337
8/1/2013	Patrick Verguet	VP	Sell	20,000	$73.15	$1,463,000.00	48,681
7/10/2013	Michael A Mussallem	CEO	Sell	29,500	$65.60	$1,935,200.00
7/5/2013	Huimin Wang	VP	Sell	4,850	$65.69	$318,596.50
6/6/2013	Michael A Mussallem	CEO	Sell	29,500	$66.25	$1,954,375.00
6/5/2013	Huimin Wang	VP	Sell	4,850	$65.11	$315,783.50
5/13/2013	Paul C Redmond	VP	Sell	5,000	$67.35	$336,750.00
5/8/2013	Michael A Mussallem	CEO	Sell	29,200	$64.24	$1,875,808.00
5/7/2013	Thomas M Abate	CFO	Sell	15,000	$63.75	$956,250.00
5/3/2013	Schack Wesley W Von	Director	Buy	1,000	$64.00	$64,000.00
5/1/2013	David E I Pyott	Director	Buy	3,000	$62.95	$188,850.00
5/1/2013	John H Kehl Jr	VP	Sell	12,500	$62.72	$784,000.00
4/26/2013	Schack Wesley W Von	Director	Buy	2,000	$64.95	$129,900.00
4/10/2013	Michael A Mussallem	CEO	Sell	35,000	$83.37	$2,917,950.00
3/13/2013	John H Kehl Jr	VP	Sell	12,500	$87.75	$1,096,875.00
10/5/2012	Huimin Wang	VP	Sell	6,250	$109.88	$686,750.00
10/4/2012	Donald E Bobo Jr	VP	Sell	11,530	$110.14	$1,269,914.20
8/9/2012	Michael A Mussallem	CEO	Sell	35,000	$98.69	$3,454,150.00

(Data available from 1/1/2013 forward)

Edwards Lifesciences (NYSE EW) News Headlines

Source:

Date	Headline
	Insider Selling: Edwards Lifesciences (EW) VP Sells 9,815 Shares of Stock www.americanbankingnews.com - May 24 at 10:10 PM
	Why Is Edwards Lifesciences (EW) Up 1.5% Since Its Last Earnings Report? www.zacks.com - May 24 at 4:37 PM
	BRIEF-Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards Sapien 3 Valve www.reuters.com - May 24 at 9:35 AM
	Form 4 Edwards Lifesciences For: May 18 Filed by: GALLAHUE KIERAN www.streetinsider.com - May 24 at 9:35 AM
	Form 4 Edwards Lifesciences For: May 18 Filed by: VON SCHACK WESLEY W www.streetinsider.com - May 24 at 9:35 AM
	Edwards Lifesciences (EW) PT Raised to $145 at RBC Capital; Reinforced Confidence Following Management Meetings www.streetinsider.com - May 24 at 9:35 AM
	Edwards Lifesciences To Present At The Bernstein 34th Annual Strategic Decisions Conference finance.yahoo.com - May 24 at 9:35 AM
	Royal Bank of Canada Raises Edwards Lifesciences (EW) Price Target to $145.00 www.americanbankingnews.com - May 23 at 1:00 PM
	Edwards Lifesciences (EW) Says Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With its SAPIEN 3 Valve www.streetinsider.com - May 22 at 4:33 PM
	Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards SAPIEN 3 Valve finance.yahoo.com - May 22 at 9:08 AM
	Edwards Lifesciences (EW) CEO Michael A. Mussallem Sells 32,900 Shares www.americanbankingnews.com - May 21 at 10:10 PM
	[$$] The AI Doctor Will See You Now finance.yahoo.com - May 21 at 9:27 AM
	Contrasting ReWalk Robotics (RWLK) and Edwards Lifesciences (EW) www.americanbankingnews.com - May 19 at 1:29 PM
	Edwards Lifesciences (EW) Enters $400M Accelerated Share Repurchase Plan www.streetinsider.com - May 18 at 10:39 AM
	Insider Selling: Edwards Lifesciences (EW) VP Sells 6,300 Shares of Stock www.americanbankingnews.com - May 16 at 10:15 PM
	$965.74 Million in Sales Expected for Edwards Lifesciences (EW) This Quarter www.americanbankingnews.com - May 15 at 3:08 AM
	Edwards Lifesciences To Webcast Annual Meeting Of Stockholders finance.yahoo.com - May 14 at 10:49 AM
	Head-To-Head Contrast: Edwards Lifesciences (EW) & Wright Medical Group (WMGI) www.americanbankingnews.com - May 14 at 1:19 AM
	Brokerages Anticipate Edwards Lifesciences (EW) to Announce $1.12 Earnings Per Share www.americanbankingnews.com - May 13 at 11:18 AM
	Edwards Lifesciences: Treating The #1 Killer In America seekingalpha.com - May 12 at 9:54 AM
	Insider Selling: Edwards Lifesciences (EW) CFO Sells 25,000 Shares of Stock www.americanbankingnews.com - May 11 at 7:25 PM
	Jean-Luc M. Lemercier Sells 5,634 Shares of Edwards Lifesciences (EW) Stock www.americanbankingnews.com - May 10 at 7:35 PM
	Edwards Lifesciences (EW) Given Average Rating of "Buy" by Brokerages www.americanbankingnews.com - May 10 at 5:25 PM
	See what the IHS Markit Score report has to say about Edwards Lifesciences Corp. finance.yahoo.com - May 9 at 9:25 AM
	Free Post Earnings Research Report: Edwards Lifesciences’ Adjusted Sales Grew 9.3%; Adjusted EPS Surged 30% finance.yahoo.com - May 8 at 9:24 AM
	Edwards Lifesciences (EW) Upgraded to "Buy" at ValuEngine www.americanbankingnews.com - May 7 at 11:10 PM
	Edwards Lifesciences (EW) VP Sells $501,334.00 in Stock www.americanbankingnews.com - May 7 at 10:26 PM
	Edwards Lifesciences (EW) CEO Michael A. Mussallem Sells 32,800 Shares www.americanbankingnews.com - May 7 at 10:26 PM
	Market Trends Toward New Normal in Anadarko Petroleum, Edwards Lifesciences ... globenewswire.com - May 7 at 9:58 AM
	Market Trends Toward New Normal in Anadarko Petroleum, Edwards Lifesciences, American Eagle Outfitters, Express, Norfolk Southern, and Investors Real Estate Trust — Emerging Consolidated Expectations, Analyst Ratings finance.yahoo.com - May 7 at 9:58 AM
	Edwards Lifesciences (EW) ASR Announcement is a Buy Signal - Evercore ISI www.streetinsider.com - May 5 at 9:32 AM
	Head-To-Head Analysis: ConforMIS (CFMS) versus Edwards Lifesciences (EW) www.americanbankingnews.com - May 5 at 3:13 AM
	Reviewing Edwards Lifesciences (EW) and Invacare (IVC) www.americanbankingnews.com - May 2 at 7:28 PM
	Insider Selling: Edwards Lifesciences (EW) CEO Sells 32,800 Shares of Stock www.americanbankingnews.com - May 2 at 7:22 PM
	Edwards launches $400M accelerated share buyback program seekingalpha.com - May 1 at 9:19 AM
	Edwards Lifesciences Enters Into Accelerated Share Repurchase Agreement finance.yahoo.com - May 1 at 9:19 AM
	Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy finance.yahoo.com - April 30 at 4:33 PM
	Edwards Lifesciences (EW) Forecasted to Earn Q3 2018 Earnings of $1.07 Per Share www.americanbankingnews.com - April 30 at 2:48 AM
	Edwards Lifesciences (EW) to Post Q3 2018 Earnings of $1.04 Per Share, Jefferies Group Forecasts www.americanbankingnews.com - April 27 at 8:50 AM
	Q2 2018 Earnings Estimate for Edwards Lifesciences (EW) Issued By William Blair www.americanbankingnews.com - April 27 at 7:44 AM
	Q2 2018 EPS Estimates for Edwards Lifesciences (EW) Lowered by Analyst www.americanbankingnews.com - April 27 at 7:44 AM
	Analysts Expect Edwards Lifesciences (EW) Will Post Quarterly Sales of $975.26 Million www.americanbankingnews.com - April 27 at 1:44 AM
	Edwards Lifesciences (EW) Expected to Earn FY2018 Earnings of $4.62 Per Share www.americanbankingnews.com - April 26 at 10:24 AM
	Q3 2018 EPS Estimates for Edwards Lifesciences Raised by William Blair (EW) www.americanbankingnews.com - April 26 at 9:44 AM
	Edited Transcript of EW earnings conference call or presentation 24-Apr-18 9:00pm GMT finance.yahoo.com - April 26 at 9:20 AM
	Stock Traders Purchase Large Volume of Put Options on Edwards Lifesciences (EW) www.americanbankingnews.com - April 26 at 6:46 AM
	Zacks: Analysts Anticipate Edwards Lifesciences (EW) Will Post Earnings of $1.17 Per Share www.americanbankingnews.com - April 25 at 11:10 PM
	Edwards Lifesciences: 1Q Earnings Snapshot www.cnbc.com - April 25 at 4:34 PM
	Edwards Lifesciences (EW) Q1 Earnings Beat, Revenues Miss finance.yahoo.com - April 25 at 4:34 PM
	Edwards Lifesciences (EW) Given "Outperform" Rating at Royal Bank of Canada www.americanbankingnews.com - April 25 at 1:30 PM

Edwards Lifesciences (NYSE:EW) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Edwards Lifesciences (NYSE:EW) Income Statement, Balance Sheet and Cash Flow Statement

Edwards Lifesciences (NYSE EW) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff